Assessment of Remote EEG Monitoring (REMI-EEG) in Pediatric Emergency and Adult Critical Care Units

Sponsor
Epitel, Inc. (Industry)
Overall Status
Enrolling by invitation
CT.gov ID
NCT05818930
Collaborator
(none)
129
1
30.8
4.2

Study Details

Study Description

Brief Summary

The goal of this observational study is to compare clinical utility between Remote EEG Monitoring (REMI) and conventional EEG in patients (6 and older) that are undergoing EEG recording in a hospital as part of their routine clinical care. The main question[s] it aims to answer are:

  • What is the concurrence of diagnosis made by epileptologist using REMI and full-EEG signals.

  • What is the proportion of participants experiencing as seizure at the time of sensor placement, compared between REMI sensor placement and full-EEG placement.

Participants will wear REMI and conventional EEG electrodes at the same time.

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: REMI

Detailed Description

Epitel has developed Epilog, a wireless wearable EEG sensor capable of transmitting EEG to a recording, display, and review platform called REMI (Remote EEG Monitoring). Epitel's REMI platform consists of the REMI tablet and four Epilog sensors. The REMI tablet requires connection to secure WiFi access, and Emergency Department and Intensive Critical Care's IT to open access to http://remi.epitel.com. The four epilog sensors communicate directly with the REMI tablet via Bluetooth connection. REMI synchronizes four Epilog sensors placed by hospital Emergency Department (ED) or intensive care unit (ICU) staff within minutes of patient arrival, thus allowing patients who are suspected of having encephalopathy to be evaluated quickly and prior to initial treatment. REMI securely transmits EEG data to its cloud server where data are processed in near real time using Persyst® Mobile software. Data can then be remotely reviewed by clinical team members.

The objective of this protocol is to demonstrate clinical utility of the Epilog EEG sensors with the REMI monitoring platform in children age 6 through adults in the pediatric emergency department and neurocritical care unit, respectively. Patients meeting entry criteria will be enrolled by a bedside clinical team member who is trained in Epilog sensor placement and use of the REMI platform. All participants will have four Epilog sensors placed, in addition to the standard of care full-EEG. The bedside clinician will be asked to make a "baseline" diagnosis based only on the clinical symptoms.

Study Design

Study Type:
Observational
Anticipated Enrollment :
129 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Assessment of Remote EEG Monitoring (REMI-EEG) in Pediatric Emergency and Adult Critical Care Units
Actual Study Start Date :
Mar 8, 2023
Anticipated Primary Completion Date :
Jun 1, 2025
Anticipated Study Completion Date :
Oct 1, 2025

Arms and Interventions

Arm Intervention/Treatment
Patients

Patients with suspected seizure events

Diagnostic Test: REMI
Diagnostic monitoring

Outcome Measures

Primary Outcome Measures

  1. Comparison of clinician's diagnostic impression between REMI and conventional electroencephalograph data. [Through the length of time that a patient is actively monitored using both REMI and a full electroencephalograph (up to 24 hours).]

    Concurrence of diagnosis made by epileptologist using REMI and full electroencephalograph signals. (I.e., a comparative count of seizure activity identified by an epileptologist using REMI EEG and using conventional EEG.)

Secondary Outcome Measures

  1. Comparison of time to identify epileptiform EEG signals between REMI and conventional electroencephalograph data. [Time Frame: Through the time of sensor placement for both REMI sensors and a full electroencephalograph (approximately up to one hour).]

    Proportion of participants seizing at the time of sensor placement, compared between REMI sensor placement and full electroencephalograph placement. (I.e., a count of seizure activity identified by an epileptologist using REMI EEG before conventional EEG is connected.)

Eligibility Criteria

Criteria

Ages Eligible for Study:
6 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Clinical EEG has been ordered for suspected seizures

  • Age 6 years or older

Exclusion Criteria:
  • Cannot undergo EEG recordings because of severe head or other injury that prevents EEG recording.

  • Transferred immediately for an operation

  • Hemodynamically unstable (SBP less than 90 mmHg) at time of EEG placement

  • Inability to place four REMI EEG sensors.

Contacts and Locations

Locations

Site City State Country Postal Code
1 University of Utah Salt Lake City Utah United States 84132

Sponsors and Collaborators

  • Epitel, Inc.

Investigators

  • Principal Investigator: Maija Holsti, MD, MPH, University of Utah
  • Principal Investigator: Amir M Arain, MD, MPH, University of Utah

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Epitel, Inc.
ClinicalTrials.gov Identifier:
NCT05818930
Other Study ID Numbers:
  • EpitelUtah22
First Posted:
Apr 19, 2023
Last Update Posted:
Apr 19, 2023
Last Verified:
Apr 1, 2023
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
Yes
Product Manufactured in and Exported from the U.S.:
Yes
Additional relevant MeSH terms:

Study Results

No Results Posted as of Apr 19, 2023